Literature DB >> 7811221

The syndrome of acquired glucocorticoid resistance in HIV infection.

G Norbiato1, M Galli, V Righini, M Moroni.   

Abstract

A certain number of HIV-infected patients (about 17% in our series) manifest symptoms of cortisol resistance--weakness, weight loss, hypertension, chronic fatigue and intense mucocutaneous melanosis--symptoms which are also typical of Addison's disease. The diagnosis of cortisol resistance is determined through the increased plasma and urinary cortisol values and limited increases in ACTH values. Compared with patients with primary glucocorticoid resistance, AIDS patients have no symptoms of mineral-corticoid or androgen excess, only of glucocorticoid deficiency at target tissues. Mononuclear leukocytes from these patients show receptor changes which consist of an increased receptor number and decreased receptor affinity for glucocorticoids. They also show defective glucocorticoid-induced inhibition of [3H]thymidine incorporation. Glucocorticoid-resistant AIDS patients have a characteristic persistent increase in interferon-alpha production. The inverse correlation between plasma values of interferon-alpha and the receptor affinity for glucocorticoids clearly suggests that interferon production is regulated by the glucocorticoid receptor: the smaller the glucocorticoid effect on lymphocyte cells is, the greater interferon production is. Owing to the antiviral effect of interferon-alpha, it is possible that glucocorticoid-resistant AIDS patients have greater defences against viral infection than other AIDS patients. As interferon-alpha is melanogenetic, its increased production may also explain the intense skin pigmentation found in patients with the glucocorticoid-resistance syndrome.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7811221     DOI: 10.1016/s0950-351x(05)80300-3

Source DB:  PubMed          Journal:  Baillieres Clin Endocrinol Metab        ISSN: 0950-351X


  8 in total

Review 1.  Hypertension in the HIV-infected patient.

Authors:  S Aoun; E Ramos
Journal:  Curr Hypertens Rep       Date:  2000-10       Impact factor: 5.369

Review 2.  Oral candidiasis, HIV, and saliva glucocorticoids.

Authors:  C O Enwonwu; V I Meeks
Journal:  Am J Pathol       Date:  1996-04       Impact factor: 4.307

Review 3.  Immune modulation of the hypothalamic-pituitary-adrenal (HPA) axis during viral infection.

Authors:  Marni N Silverman; Brad D Pearce; Christine A Biron; Andrew H Miller
Journal:  Viral Immunol       Date:  2005       Impact factor: 2.257

4.  HIV and symptoms of depression are independently associated with impaired glucocorticoid signaling.

Authors:  Mandakh Bekhbat; C Christina Mehta; Sean D Kelly; Aimee Vester; Ighovwerha Ofotokun; Jennifer Felger; Gina Wingood; Kathryn Anastos; Deborah R Gustafson; Seble Kassaye; Joel Milam; Bradley Aouizerat; Kathleen Weber; Elizabeth T Golub; Michelle Floris Moore; Ralph Diclemente; Margaret Fischl; Mirjam-Colette Kempf; Pauline Maki; Gretchen N Neigh
Journal:  Psychoneuroendocrinology       Date:  2018-06-18       Impact factor: 4.905

Review 5.  HIV and the Pituitary Gland: Clinical and Biochemical Presentations.

Authors:  Joyce Youssef; Rohan Sadera; Dushyant Mital; Mohamed H Ahmed
Journal:  J Lab Physicians       Date:  2021-05-19

6.  A Rare Mechanism of Hyponatremia in HIV Disease.

Authors:  Hector Madariaga; Aswini Kumar; Apurv Khanna
Journal:  Am J Case Rep       Date:  2015-10-05

7.  The Syndrome of Inappropriate Secretion of Anti-Diuretic Hormone (SIADH) and Brucellosis.

Authors:  Keziban Aslı Bala; Murat Doğan; Sultan Kaba; Sinan Akbayram; Oktay Aslan; Selami Kocaman; Gülsüm İclal Bayhan; Lokman Üstyol; Nihat Demir
Journal:  Med Sci Monit       Date:  2016-09-03

8.  HIV-1 Tat and morphine decrease murine inter-male social interactions and associated oxytocin levels in the prefrontal cortex, amygdala, and hypothalamic paraventricular nucleus.

Authors:  Sara R Nass; Arianna R S Lark; Yun K Hahn; Virginia D McLane; Therese M Ihrig; Liangru Contois; T Celeste Napier; Pamela E Knapp; Kurt F Hauser
Journal:  Horm Behav       Date:  2021-06-23       Impact factor: 3.492

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.